Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes .
| FactSnippet No. 736,907 |
10 Facts About Lenalidomide
3.
Lenalidomide is effective at inducing a complete or "very good partial" response and improves progression-free survival.
| FactSnippet No. 736,909 |
4.
Lenalidomide was approved by the FDA on 27 December 2005 for patients with low- or intermediate-1-risk myelodysplastic syndromes who have chromosome 5q deletion syndrome with or without additional cytogenetic abnormalities.
| FactSnippet No. 736,910 |
5.
Lenalidomide is approved by FDA as a specialty drug requiring a specialty pharmacy distribution for mantle cell lymphoma in patients whose disease has relapsed or progressed after at least two prior therapies, one of which must have included the medicine bortezomib.
| FactSnippet No. 736,911 |
6.
Lenalidomide is related to thalidomide, which is known to be teratogenic.
| FactSnippet No. 736,912 |
7.
Lenalidomide has been used to successfully treat both inflammatory disorders and cancers in the past ten years.
| FactSnippet No. 736,913 |
8.
Lenalidomide has a broad range of activities that can be exploited to treat many hematologic and solid cancers.
| FactSnippet No. 736,914 |
10.
Lenalidomide is undergoing clinical trial as a treatment for Hodgkin's lymphoma, as well as non-Hodgkin's lymphoma, chronic lymphocytic leukemia and solid tumor cancers, such as carcinoma of the pancreas.
| FactSnippet No. 736,916 |